Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Video and Gait Assessment After Dysport for Equinovarus
NCT03501043Phase 4Completed
- Sponsor
- Einstein Healthcare Network
- Start
- Jun 2018
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in congenital talipes equinovarus (CTEV), sponsored by Einstein Healthcare Network. Primary endpoints: Self-Selected Velocity (SSV), Maximal Velocity (MV) and 1 more. Started Jun 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
congenital talipes equinovarus (CTEV)
Beyond the preview
Go deeper on NCT03501043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03501043.